阿达木单抗治疗银屑病关节炎伴活动性皮肤病患者中最小疾病活动度的预测与获益:ADEPT试验
基于ADEPT试验,分析银屑病关节炎伴活动性皮肤病患者在144周内达到最小疾病活动度(MDA)的比例、基线预测因素及其与生活质量相关患者报告结局的关联。多变量分析证实基线HAQ-DI评分较高是 later 时间点未能达到MDA的显著预测因素,达到MDA与更好的独立生活质量相关PROs相关。
要点
- 基线HAQ-DI评分较高是 later 时间点未能达到MDA及持续MDA的最一致预测因素。
- 达到MDA者较未达到者生活质量相关PROs显著更好,且从基线到第24周改善更大。
- 不同MDA组分的达到似乎呈治疗依赖性。
核心结论
- 基线HAQ-DI评分较高是降低 later 时间点达到MDA及持续MDA可能性的最一致基线因素。
- 达到MDA与更好的独立生活质量相关PROs相关。
研究设计与样本
- ADEPT试验(阿达木单抗治疗银屑病关节炎有效性试验)的事后分析,评估144周内达到MDA及其各组分的情况。
- 采用单变量和多变量分析识别预测个别时间点(第12至144周)达到MDA或持续MDA(间隔12周的连续两个时间点均达到MDA)的基线特征。
- 在第24周和第144周评估独立生活质量相关PROs与MDA达到的关联。
主要发现
- 单变量分析中,较高的基线患者疼痛评估、压痛关节计数(TJC)、附着点炎和HAQ-DI评分与 later 时间点达到MDA的可能性较低显著相关。
- 多变量分析证实较高的基线HAQ-DI是 later 时间点未能达到MDA的显著预测因素。
- 达到持续MDA与较低的基线TJC和HAQ-DI评分相关。
- 达到MDA者较未达到者生活质量相关PROs显著更好,且从基线到第24周PROs改善更大。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the association of MDA status with independent quality of life (QoL)-related patient-reported outcomes (PROs). METHODS: Univariate and multivariate analyses were used to identify the baseline characteristics that predicted achievement of MDA at individual time points (weeks 12 through 144) or sustained MDA (achievement of MDA at 2 consecutive time points 12 weeks apart). The association of independent QoL-related PROs with MDA achievement was evaluated at weeks 24 and 144. RESULTS: In univariate analyses, higher baseline patient assessment of pain, tender joint count (TJC), enthesitis and Health Assessment Questionnaire-Disability Index (HAQ-DI) score were significantly associated with lower likelihood of achieving MDA at later time points. Multivariate analyses confirmed higher baseline HAQ-DI as a significant predictor for failure to achieve MDA at later time points. Achievement of sustained MDA was associated with lower baseline TJC and HAQ-DI score. Achievement of different MDA components appeared to be treatment dependent. MDA achievers had significantly better QoL-related PROs and greater improvements in PROs from baseline to week 24 compared with non-achievers. CONCLUSIONS: Higher HAQ-DI score was the most consistent baseline factor that decreased the likelihood of achieving MDA and sustained MDA at later time points. Achieving MDA was associated with better independent QoL-related PROs.
引用
- Mease PJ, Kavanaugh A, Coates LC, et al. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open. 2017. PMID: 29225916. doi:10.1136/rmdopen-2016-000415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。